Compare · Head-to-head
LL-37 vs Melanotan II.
Evidence, risk, regulatory flags, cost, and vendor coverage compared side by side. We don’t sell peptides — we help you choose between them.
Which should you research first?
Start with LL-37, then use the table to confirm fit.
LL-37 is the cleaner first read based on the current evidence, risk, and regulatory data stored for this pair. The right answer can still change if your goal, sport testing status, vendor constraints, or monitoring tolerance makes the other option a better fit.
Comparison next step
Personalize this head-to-head.
Take the quiz before converting a comparison into a compound, vendor, or protocol decision.
01· Subject
LL-37
Human antimicrobial peptide with topical wound healing studies. Antimicrobial therapeutic claims trigger regulatory scrutiny.
01 · At a glance
| Decision factor | LL-37 | Melanotan II |
|---|---|---|
| Primary fit | tissue repair & recovery and immune support comparisons | skin & hair and sexual health & libido comparisons |
| Evidence | Tier B-C | Tier C |
| Risk | high | high |
| Experience level | intermediate | advanced |
| Budget tier | mid | budget |
| Administration route | topical | subcutaneous |
02 · Use case & timing
| Decision factor | LL-37 | Melanotan II |
|---|---|---|
| Goal fit | Tissue Repair & Recovery, Immune Support, Skin & Hair | Skin & Hair, Sexual Health & Libido |
| What users compare it for | Wound healing support; antimicrobial properties in topical application. | Pigmentation changes (tanning); sexual arousal effects. NOT a controlled therapeutic product. |
| Onset timeline | Wound endpoints measured over weeks. | Pigmentation changes can occur quickly; adverse events can be acute. |
| Main tradeoff | Potential upside comes with much more safety and screening caution than lower-risk alternatives. | Potential upside comes with much more safety and screening caution than lower-risk alternatives. |
03 · Safety & restrictions
| Decision factor | LL-37 | Melanotan II |
|---|---|---|
| Adverse effects | Topical appears tolerable; systemic use carries different risk profile. | FDA cites serious adverse events: melanoma, posterior reversible encephalopathy syndrome, sympathomimetic toxidrome, priapism. Immunogenicity/impurity concerns. |
| Contraindications | No formal label. | High risk across the board; unlicensed and unapproved. |
| Interaction notes | Unknown. | Unknown; risk may increase with UV exposure behaviors and stimulant-like exposures. |
| Regulatory status | Not approved | Not approved |
| FDA flag | FDA status unclear | FDA compounding caution |
| WADA status | Not listed | Status unclear |
04 · Age & monitoring
| Decision factor | LL-37 | Melanotan II |
|---|---|---|
| Supported age ranges | No age guidance yet | No age guidance yet |
| Life-stage note | Not yet documented | Not yet documented |
| Monitoring burden | Not specified | Not specified |
| Follow-up cadence | Not yet documented | Not yet documented |
05 · Cost & sourcing
| Decision factor | LL-37 | Melanotan II |
|---|---|---|
| Typical cycle cost | No reliable estimate yet | $80.00 |
| Estimated monthly cost | No reliable estimate yet | $53.33 |
| Cost confidence | No estimate | High confidence |
06 · Before you buy
| Decision factor | LL-37 | Melanotan II |
|---|---|---|
| Tracked vendor listings | 0 listings | 3 listings |
| Sourcing note | No tracked product page yet, so sourcing takes more manual review. | Product format varies by listing, so double-check route, concentration, and presentation. |
| Stack-friendly? | Usually stack-friendly | Usually stack-friendly |
Sources and review notes
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks - U.S. Food and Drug Administration - accessed 2026-05-15
Used for FDA compounding-risk context and peptide safety flags.
- The Prohibited List - World Anti-Doping Agency - accessed 2026-05-15
Used for athlete-facing WADA risk and peptide-class restrictions.
- Peptide therapeutics: current status and future directions - PubMed / Nature Reviews Drug Discovery - accessed 2026-05-15
Used for broad peptide-therapeutics background and evidence framing.
Still deciding
Get a plan tailored to you.
The quiz factors in your goal, experience, and risk tolerance to surface a starting compound and dosing range.